Instil Bio (TIL) Stock Price, News & Analysis

Company Overview

Instil Bio plc is a clinical‐stage biotechnology company focused on the discovery, development and delivery of off‐the‐shelf cell therapies for cancer and other serious diseases. The company’s proprietary Instinct Platform leverages high‐parameter single‐cell multiomics, machine learning and immunological screening to identify and engineer natural killer (NK) and T cell products with enhanced potency, persistence and safety. Instil Bio’s technology backbone is designed to accelerate the translation of novel cellular candidates through in vitro and in vivo models, providing a systematic approach to next‐generation immuno‐oncology therapies.

The company’s pipeline includes lead programs such as INB‐101, an allogeneic, engineered NK cell therapy currently in Phase 1 clinical evaluation for refractory solid tumors, and a series of follow‐on candidates collectively known as the INB‐200 series. These programs employ targeted genetic modifications to improve tumor antigen recognition, enhance cell trafficking and resist the immunosuppressive tumor microenvironment. Beyond oncology, Instil Bio is exploring applications in rare hematological disorders and infectious diseases by adapting its platform to different immune cell types and therapeutic modalities.

Founded in 2020 and headquartered in the United Kingdom and United States, Instil Bio combines multidisciplinary expertise in immunology, genomics and cell therapy manufacturing. The company completed its Nasdaq listing via a business combination in 2022, positioning it to advance multiple clinical programs while expanding its research and manufacturing capabilities. Led by a management team with deep experience in biotech R&D and commercialization, Instil Bio aims to establish a new standard for the discovery and development of engineered cell therapies on a global scale.

Key Stats

• Today's Range: $17.53 to $18.21
• 50-Day Range: $16.65 to $31.50
• 52-Week Range: $10.80 to $55.19
• Volume: 104,849 shs
• Average Volume: 197,998 shs
• Market Capitalization: $122.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $88.50
• Consensus Rating: Moderate Buy

Instil Bio Stock Analysis - MarketRank™

Instil Bio scored higher than 55% of companies evaluated by MarketBeat, and ranked 518th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Instil Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Instil Bio has a consensus price target of $88.50, representing about 389.0% upside from its current price of $18.10.

Amount of Analyst Coverage

Instil Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Instil Bio are expected to grow in the coming year, from ($13.32) to ($11.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Instil Bio is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Instil Bio is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Instil Bio has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.51% of the float of Instil Bio has been sold short.

Short Interest Ratio / Days to Cover

Instil Bio has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Instil Bio has recently increased by 0.04%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Instil Bio does not currently pay a dividend.

Dividend Growth

Instil Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

24.51% of the float of Instil Bio has been sold short.

Short Interest Ratio / Days to Cover

Instil Bio has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Instil Bio has recently increased by 0.04%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Instil Bio this week, compared to 1 article on an average week.

Search Interest

9 people have searched for TIL on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Instil Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $701,700.00 in company stock.

Percentage Held by Insiders

47.20% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TIL Stock Analysis - Frequently Asked Questions

How have TIL shares performed this year?

Instil Bio's stock was trading at $19.09 at the beginning of the year. Since then, TIL shares have decreased by 5.2% and is now trading at $18.10.

How were Instil Bio's earnings last quarter?

Instil Bio, Inc. (NASDAQ:TIL) released its earnings results on Wednesday, August, 13th. The company reported ($3.24) earnings per share for the quarter, missing the consensus estimate of ($1.72) by $1.52.

When did Instil Bio's stock split?

Shares of Instil Bio reverse split before market open on Friday, December 8th 2023.The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Instil Bio IPO?

Instil Bio (TIL) raised $250 million in an IPO on Friday, March 19th 2021. The company issued 13,900,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities acted as the underwriters for the IPO.

How do I buy shares of Instil Bio?

Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Instil Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Instil Bio investors own include Tesla (TSLA), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Taysha Gene Therapies (TSHA), Viking Therapeutics (VKTX), Golden Minerals (AUMN) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/03/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TIL
• CIK: 1625584
• Web: www.tillcap.com
• Phone: 972-499-3350
• Fax: N/A
• Employees: 410
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Instil Bio: $88.50
• High Price Target: $125.00
• Low Price Target: $52.00
• Potential Upside/Downside: +389.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($12.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.14 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -54.32%
• Return on Assets: -33.65%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 14.97
• Quick Ratio: 14.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $25.96 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 6,750,000
• Free Float: 3,565,000
• Market Cap: $122.18 million
• Optionable: No Data
• Beta: 2.07